The research in the Cheal lab focuses on the development of theranostic molecular-targeted radionuclides (radiopharmaceutical) therapies, especially for the treatment of solid human tumors. We work closely with our collaborators at Memorial Sloan Kettering Cancer Center to harness lu DOTA-TATE (DOTA)-based radiohapten capture for pre-targeted imaging and radioimmunotherapy (PRIT) applications. We specialize in the synthesis and evaluation of DOTA-PRIT radiohaptens for both β-particle-emitter (177Lu) and α-particle-emitter (225Ac and 212Pb) radiopharmaceutical therapy. Also, we develop DOTA-PRIT radiohaptens for non-invasive imaging with positron emission tomography (PET) or single-photon emission computerized tomography (SPECT) for dosimetry and treatment planning. For these novel radiohaptens, we optimize radiosynthesis, perform in vitro characterization of affinity and stability, optimize in vivo targeting efficiency, and establish preclinical profiles of anti-tumor efficacy and toxicity. We have experience in bioconjugation, radiochemistry, and radiopharmacology of a broad range of tumor-targeting vectors. Our mission is to catalyze the development and translation of radiopharmaceuticals by effectively collaborating with experts across multiple disciplines (inorganic chemistry, organic synthesis, immunology, medical physics, nuclear medicine).